CN115894279A - Olive oil ceramide and synthesis method and application thereof - Google Patents
Olive oil ceramide and synthesis method and application thereof Download PDFInfo
- Publication number
- CN115894279A CN115894279A CN202211493023.1A CN202211493023A CN115894279A CN 115894279 A CN115894279 A CN 115894279A CN 202211493023 A CN202211493023 A CN 202211493023A CN 115894279 A CN115894279 A CN 115894279A
- Authority
- CN
- China
- Prior art keywords
- ceramide
- acid
- olive oil
- weight percent
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940106189 ceramide Drugs 0.000 title claims abstract description 180
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 title claims abstract description 171
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 title claims abstract description 171
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 title claims abstract description 171
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 title claims abstract description 171
- 235000008390 olive oil Nutrition 0.000 title claims abstract description 105
- 239000004006 olive oil Substances 0.000 title claims abstract description 105
- 238000001308 synthesis method Methods 0.000 title description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 46
- 239000000194 fatty acid Substances 0.000 claims abstract description 46
- 229930195729 fatty acid Natural products 0.000 claims abstract description 46
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 46
- 229940033329 phytosphingosine Drugs 0.000 claims abstract description 15
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 claims abstract description 13
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 claims abstract description 13
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims abstract description 13
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 11
- 230000035876 healing Effects 0.000 claims abstract description 11
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 claims abstract description 11
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- 230000036541 health Effects 0.000 claims abstract description 4
- OTKJDMGTUTTYMP-ROUUACIJSA-N Safingol ( L-threo-sphinganine) Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ROUUACIJSA-N 0.000 claims abstract 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 32
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 32
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 28
- 239000005642 Oleic acid Substances 0.000 claims description 26
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 25
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 25
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 25
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 25
- -1 sphingoid compound Chemical class 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 235000021314 Palmitic acid Nutrition 0.000 claims description 16
- 235000021355 Stearic acid Nutrition 0.000 claims description 16
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 16
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 16
- 229960004488 linolenic acid Drugs 0.000 claims description 16
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 16
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 16
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 16
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 16
- 239000008117 stearic acid Substances 0.000 claims description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 15
- 235000020778 linoleic acid Nutrition 0.000 claims description 15
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 15
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims description 14
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims description 12
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 12
- 238000003786 synthesis reaction Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 claims description 10
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 9
- 102000008186 Collagen Human genes 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 9
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical group Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 8
- 230000008439 repair process Effects 0.000 claims description 8
- 230000008591 skin barrier function Effects 0.000 claims description 8
- 230000002087 whitening effect Effects 0.000 claims description 8
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 235000006708 antioxidants Nutrition 0.000 claims description 7
- 229940108623 eicosenoic acid Drugs 0.000 claims description 7
- BITHHVVYSMSWAG-UHFFFAOYSA-N eicosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCC(O)=O BITHHVVYSMSWAG-UHFFFAOYSA-N 0.000 claims description 7
- GEHPRJRWZDWFBJ-FOCLMDBBSA-N (2E)-2-heptadecenoic acid Chemical compound CCCCCCCCCCCCCC\C=C\C(O)=O GEHPRJRWZDWFBJ-FOCLMDBBSA-N 0.000 claims description 6
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 235000021357 Behenic acid Nutrition 0.000 claims description 6
- 102000016942 Elastin Human genes 0.000 claims description 6
- 108010014258 Elastin Proteins 0.000 claims description 6
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 claims description 6
- 235000021360 Myristic acid Nutrition 0.000 claims description 6
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 6
- 235000021319 Palmitoleic acid Nutrition 0.000 claims description 6
- 206010051246 Photodermatosis Diseases 0.000 claims description 6
- 230000003712 anti-aging effect Effects 0.000 claims description 6
- 229940116226 behenic acid Drugs 0.000 claims description 6
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 6
- 229920002549 elastin Polymers 0.000 claims description 6
- 235000021353 Lignoceric acid Nutrition 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- QZZGJDVWLFXDLK-UHFFFAOYSA-N tetracosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(O)=O QZZGJDVWLFXDLK-UHFFFAOYSA-N 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 150000003410 sphingosines Chemical class 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000032683 aging Effects 0.000 abstract description 2
- 230000004888 barrier function Effects 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 36
- 239000000047 product Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 150000001783 ceramides Chemical class 0.000 description 9
- 239000004519 grease Substances 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 9
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 102000016387 Pancreatic elastase Human genes 0.000 description 7
- 108010067372 Pancreatic elastase Proteins 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical group [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 238000006482 condensation reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000012159 carrier gas Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- WYURNTSHIVDZCO-SVYQBANQSA-N oxolane-d8 Chemical compound [2H]C1([2H])OC([2H])([2H])C([2H])([2H])C1([2H])[2H] WYURNTSHIVDZCO-SVYQBANQSA-N 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- FIXXCHAZHOXPQG-ZNWYJMOFSA-N (E,2S,3R)-2-aminooctadec-4-ene-1,3-diol octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO FIXXCHAZHOXPQG-ZNWYJMOFSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002849 elastaseinhibitory effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 125000002657 sphingoid group Chemical group 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the technical field of biological medicines, and discloses olive oil ceramide which is obtained by reacting olive oil fatty acid with sphingoid compounds, wherein the sphingoid compounds are selected from sphingosine, phytosphingosine and dihydrosphingosine. The olive oil ceramide has excellent performances in the aspects of repairing natural barriers of skin, resisting inflammation, healing tissues, resisting aging and the like, and has wide application prospects in the fields of cosmetics, health products, biological medicines and the like.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to olive oil ceramide, a synthetic method and application thereof.
Background
Ceramide (Ceramide, also called molecular nail) naturally exists in skin, is a very important component of skin barrier (stratum corneum) and is up to 40-50 wt%, and is a sphingolipid consisting of sphingoid long-chain bases and fatty acids, wherein the carbon chain length, the unsaturation degree and the hydroxyl number of the sphingoid part and the fatty acid part can be changed, and the Ceramide represents a compound. Ceramides exhibit excellent properties in regulating skin barrier function, restoring skin moisture, and enhancing adhesion between skin keratinocytes, etc.
Due to the importance of ceramides, many cosmetic and pharmaceutical companies are researching and developing corresponding products. The natural plant-derived ceramide can form an effective skin barrier to prevent water loss and resist external damage due to a more sustainable and more environment-friendly raw material source and a similar component to skin ceramide, and can possibly become a next-generation environment-friendly, safe and reliable ceramide product.
The olive oil is generally olive oil grease, is prepared by directly cold pressing fresh olive fruits, does not undergo heating and chemical treatment, retains natural nutritional ingredients, and is known as 'liquid gold', 'vegetable oil queen', 'Mediterranean nectar' in the west. Olive oil is rich in oleic acid, which is a monounsaturated fatty acid, and also vitamin a, vitamin B, vitamin D, vitamin E, vitamin K, antioxidants, and the like, and is considered to be the most suitable oil for the human body among the oils found so far. The data show that the olive oil can reduce the synthesis of catecholamine, inhibit the increase of active oxygen generation, lipid peroxidation and protein carbonylation of the skin, and has good effects of resisting aging and oxidation, whitening and beautifying, shrinking pores and the like. Because it contains abundant seborrheic vitamin, it is very beneficial to skin, and is a safe and reliable good cosmetic product, so that it is known as "edible cosmetic product". In addition, research shows that the olive oil has the effects of promoting blood circulation, reducing cardiovascular diseases, promoting the development of bones and nervous systems, losing weight, treating injuries, slowing down the functional degeneration of nerve cells of the old and the like in the aspect of medicine, and the olive oil can also be used as a sedative and an auxiliary treatment means for treating jaundice and gallstones.
Disclosure of Invention
The invention aims to provide ceramide synthesized by olive oil fatty acid from plants.
Another object of the present invention is to provide a method for synthesizing olive oil ceramide using olive oil or olive oil fatty acid, which are naturally derived from plants and easily available, as a raw material.
It is another object of the present invention to provide the use of olive oil ceramide.
In order to achieve one of the purposes, the invention adopts the following technical scheme:
in a first aspect of the invention, an olive oil ceramide, obtained by reacting an olive oil fatty acid with a sphingoid compound selected from sphingosine, phytosphingosine, dihydrosphingosine.
The reaction can be a chemical synthesis reaction (as detailed below), or a microbial fermentation method, namely, pichia pastoris or saccharomyces cerevisiae is used for fermentation under certain environment to obtain sphingoid compounds, and then fatty acid is added to finally obtain ceramide; or fermenting olive oil as raw material with proper strain to obtain olive oil ceramide.
Sphingosine refers to 2-amino-4-octadecene-1,3-diol, phytosphingosine refers to 2-amino-octadecane-1,3,4-triol, and dihydrosphingosine refers to 2-amino-octadecane-1,3-diol.
Further, the olive oil fatty acid is obtained by hydrolysis of olive oil.
Further, the olive oil fatty acid contains 20 to 83wt% oleic acid, preferably 55 to 83wt% oleic acid.
Further, the olive oil fatty acid contains 7.5 to 20wt% of palmitic acid.
Further, the olive oil fatty acid contains 3.5 to 70wt% linoleic acid, preferably 3.5 to 21wt% linoleic acid.
Further, the olive oil fatty acid contains 0.5 to 5wt% of stearic acid.
Further, the olive oil fatty acid contains 0.1-1.0 wt% of linolenic acid.
In addition, the olive oil fatty acid also contains 0 to 3.5 weight percent of palmitoleic acid, 0 to 0.6 weight percent of arachidic acid, 0 to 0.4 weight percent of eicosenoic acid, 0 to 0.3 weight percent of heptadecanoic acid, 0 to 0.3 weight percent of heptadecenoic acid, 0 to 0.2 weight percent of behenic acid, 0 to 0.2 weight percent of tetracosanoic acid and 0 to 0.05 weight percent of myristic acid.
The olive oil fatty acid has the following components: 20 to 83 weight percent of oleic acid, 7.5 to 20 weight percent of palmitic acid, 3.5 to 70 weight percent of linoleic acid, 0.5 to 5 weight percent of stearic acid, 0.1 to 1.0 weight percent of linolenic acid, 0 to 3.5 weight percent of palmitoleic acid, 0 to 0.6 weight percent of arachidic acid, 0 to 0.4 weight percent of eicosenoic acid, 0 to 0.3 weight percent of heptadecanoic acid, 0 to 0.3 weight percent of heptadecenoic acid, 0 to 0.2 weight percent of behenic acid, 0 to 0.2 weight percent of tetracosanic acid and 0 to 0.05 weight percent of myristic acid.
The main component of olive oil fatty acid is oleic acid, other fatty acids include linoleic acid, palmitic acid, stearic acid and linolenic acid, which are essential components, and the content of each component is different under the influence of tree species, soil, climate, producing area, picking season and extraction process, while palmitoleic acid, arachidic acid, eicosenoic acid, heptadecanoic acid, heptadecenoic acid, behenic acid, lignoceric acid and myristic acid are optional components or unnecessary components.
Olive oil ceramide, the composition of which comprises: oleic acid ceramide, linoleic acid ceramide, palmitic acid ceramide, stearic acid ceramide, linolenic acid ceramide; since fatty acids all participate in the same reaction, and the mass ratio of ceramide after the reaction does not change much, the composition of olive oil fatty acid can be referred to, and the composition of olive oil ceramide is: 20 to 83 weight percent of oleic acid ceramide, 7.5 to 20 weight percent of palmitic acid ceramide, 3.5 to 70 weight percent of linoleic acid ceramide, 0.5 to 5 weight percent of stearic acid ceramide and 0.1 to 1.0 weight percent of linolenic acid ceramide; the preferred composition is: 55 to 83 weight percent of oleic acid ceramide, 7.5 to 20 weight percent of palmitic acid ceramide, 3.5 to 21 weight percent of linoleic acid ceramide, 0.5 to 5 weight percent of stearic acid ceramide, and 0.1 to 1.0 weight percent of linolenic acid ceramide. The content of each component is different due to different contents of olive oil fatty acid or fatty acid in the oil. In addition, the olive oil ceramide also comprises ceramide obtained by reacting one or more of palmitoleic acid, arachidic acid, eicosenoic acid, heptadecylic acid, heptadecenoic acid, behenic acid, lignoceric acid and myristic acid with sphingoid compounds, namely, 0-3.5 wt% of palmitoleic acid ceramide, 0-0.6 wt% of arachidic acid ceramide, 0-0.4 wt% of eicosenoic acid ceramide, 0-0.3 wt% of heptadecenoic acid ceramide, 0-0.2 wt% of behenic acid ceramide, 0-0.2 wt% of lignoceric acid ceramide and 0-0.05 wt% of myristic acid ceramide.
Olive oil ceramide, the composition of which comprises: oleic acid ceramide, palmitic acid ceramide, linoleic acid ceramide; oleic acid ceramide 20-83 wt%, preferably 55-83 wt%, palmitic acid ceramide 7.5-20 wt%, linoleic acid ceramide 3.5-70 wt%, preferably 3.5-21 wt%.
Further, the olive oil ceramide comprises stearic acid ceramide, and the stearic acid ceramide accounts for 0.5-5 wt%.
Furthermore, the olive oil ceramide comprises linolenic acid ceramide, and the linolenic acid ceramide accounts for 0.1-1.0 wt%.
The oleic acid ceramide is obtained by condensation reaction of oleic acid and sphingoid compounds, and comprises oleic acid phytosphingosine ceramide, oleic acid sphingosine ceramide and oleic acid dihydrosphingosine ceramide; the linoleic acid ceramide is obtained by condensation reaction of linoleic acid and sphingoid compounds, and comprises linoleic acid phytosphingosine ceramide, linoleic acid sphingosine ceramide, and linoleic acid dihydrosphingosine ceramide; the palmitic acid ceramide is obtained by condensation reaction of palmitic acid and sphingoid compounds, and comprises palmitic acid phytosphingosine ceramide, palmitic acid sphingosine ceramide, and palmitic acid dihydrosphingosine ceramide; the stearic acid ceramide is obtained by condensation reaction of stearic acid and sphingoid compounds, and comprises stearic acid phytosphingosine ceramide, stearic acid sphingosine ceramide and stearic acid dihydrosphingosine ceramide; linolenic acid ceramide is obtained by condensation reaction of linolenic acid and sphingoid compounds, and comprises linolenic acid phytosphingosine ceramide, linolenic acid sphingosine ceramide, and linolenic acid dihydrosphingosine ceramide; arachidic acid ceramide, eicosenoic acid ceramide, and the like.
In a second aspect of the present invention, a method for synthesizing olive oil ceramide comprises the following steps:
reacting olive oil fatty acid with sphingoid compound under the condition of condensing agent, wherein the condensing agent is EDCI and Et 3 N。
Further, the olive oil fatty acid, sphingoid compound, EDCI, et 3 The molar ratio of N is 1: (1-1.5): (1-2): (1-2), wherein the solvent for reaction is at least one of dichloromethane, tetrahydrofuran, ethyl acetate and acetonitrile.
Olive oil, which is generally available on the market in the form of fat and needs to be hydrolysed to olive oil fatty acids, therefore it also comprises the following steps:
the olive oil fatty acid is obtained by hydrolyzing olive oil through saponification reaction.
Further, the saponification reaction is hydrolysis of olive oil grease in potassium hydroxide solution.
Further, the mass ratio of the olive oil grease to the potassium hydroxide is 1: (1-2).
In a third aspect of the present invention, the use of olive oil ceramide in cosmetics, pharmaceuticals, dietary foods or health products.
Further, the olive oil ceramide has at least one of skin barrier repair, tissue healing, anti-aging, anti-inflammatory, anti-photoaging, anti-oxidation, collagen synthesis promotion, elastin enhancement, and whitening effects.
A composition comprising olive oil ceramide, said composition having at least one of skin barrier repair, tissue healing, anti-aging, anti-inflammatory, anti-photoaging, anti-oxidant, collagen synthesis promoting, elastin increasing, and whitening effects.
The composition contains acceptable adjuvants including one or more of solubilizer, antiseptic, antioxidant, pH regulator, penetration enhancer, liposome, humectant, thickener, chelating agent, skin feeling regulator, surfactant, emulsifier, essence and pigment; the composition is in the form of cream, emulsion, solution, pellicle, aerosol or spray.
The invention has the following beneficial effects:
the olive oil fatty acid belongs to naturally formed fatty acid, the main component is monounsaturated fatty acid-oleic acid or linoleic acid, and in addition, palmitic acid, stearic acid, linolenic acid and the like are also contained, and the olive oil ceramide is prepared by mild reaction with sphingoid compounds naturally existing in skin, shows excellent performance in the aspects of repairing, antioxidation, anti-aging and the like of natural barriers of the skin, and has wide application prospect in the fields of cosmetics, health care products, biological medicines and the like.
1. It is more effective than ceramide alone. Different ceramides have different effects due to their structural differences, and ceramides with a single structure generally have poor comprehensive effects. The scheme is based on a bionic idea, olive oil grease or fatty acid from natural sources is used as a raw material to synthesize the composite ceramide so as to make up for the difference of the efficacies of different ceramides, and trace fatty acid in olive sources can form trace ceramide, so that the function supplement effect is achieved.
2. Compared with compounded ceramide, the effect is better. Except oleic acid (or grease), the olive oil also contains components such as vitamins and polyphenol, and the like, the nutrient substances have the effects of moistening skin, enhancing cell activity and the like, and the ceramide synthesized by the olive oil has the synergistic effect with other active components contained in the olive oil, and has better effect compared with the ceramide compounded according to similar proportion.
3. The cost is lower. The method of the invention can quickly obtain the composition compounded by various ceramides, the olive oil grease of plant source or the fatty acid thereof has wide source, easy commercial acquisition, lower cost, more environmental protection and economy, and is different from the idea of mixing and compounding different single ceramides, the fatty acid of single component has high raw material price, and the different ceramides are respectively produced and then compounded, thereby increasing the preparation cost.
4. The synthetic method is simple. The method can adopt chemical synthesis to realize one-step preparation of various ceramides, and can also use a microbial fermentation method.
Drawings
FIGS. 1 and 2 are bar graphs of the cell proliferation activity test results of example 4;
FIG. 3 shows the results of the measurement of cell migration ability in example 5;
FIG. 4 is a bar graph of the elastase inhibition of example 6;
FIG. 5 is a bar graph of the anti-inflammatory repair efficacy assays of example 7;
FIG. 6 is a bar graph showing the expression level of MMP1 in example 8;
FIGS. 7 and 8 are bar graphs of the oxidation resistance test results of example 9;
fig. 9 is a bar graph of the results of the whitening activity test of example 10.
Detailed Description
The present invention will be further described with reference to the following specific examples.
EDCI means 1-ethyl- (3-dimethylaminopropyl) carbodiimide, et 3 N refers to triethylamine. The silica gel column chromatography uses Qingdao marine silica gel (particle size 0.040-0.063 mm). Thin Layer Chromatography (TLC) was performed using a 60F254 silica gel plate, and TLC developed using UV light (254 nm) or iodine. NMR spectra were characterized using a Bruker DPX 400 nuclear magnetic resonance apparatus, 1 h NMR is 400MHz, solvent is deuterated methanol, deuterated DMSO or deuterated tetrahydrofuran, and Tetramethylsilane (TMS) is used as internal standard. Chemical shifts are in ppm and coupling constants are in Hz. In that 1 In H NMR, δ represents chemical shift, s represents singlet, d represents doublet, t represents triplet, q represents quartet, and m represents multiplet.
Example 1
Synthesis of ceramide from olive oil fatty acid and phytosphingosine
The first step is as follows: 50g of olive oil grease is dissolved in 60mL of tetrahydrofuran, cooled in ice bath, 100mL of potassium hydroxide (25 wt%) solution is added dropwise, and the mixture is heated to room temperature after the dropwise addition is finished to react until the TLC detection reaction is finished.
And (3) post-treatment: adding dilute hydrochloric acid (3N) to adjust pH to 3, adding 150mL ethyl acetate to extract water phase, adding 100mL saturated salt water to wash once, adding anhydrous Na to organic phase 2 SO 4 Drying, filtering and vacuum concentrating to obtain 40g olive oil fatty acid.
The second step is that: mixing olive oil fatty acid (50 mmol, molecular weight is calculated as oleic acid), EDCI (60 mmol), et 3 N (60 mmol) was added to 250mL in a round-bottom flask, followed by addition of 100mL of dichloromethane, followed by stirring at room temperature for 1 hour, and phytosphingosine (60 mmol) was added to the reaction system, followed by stirring at room temperature, until completion of the TLC detection reaction.
And (3) post-treatment: adding water to quench and react, separating an organic layer, drying, filtering, concentrating in vacuum, washing by a solvent to obtain the olive oil ceramide, analyzing a product by HPLC, and carrying out HPLC chromatographic conditions: using Shimadzu high performance liquid chromatograph (LC-2030C 3DPlus), the column temperature was adjusted by Innoval ODS-2.6 × 250mm,5 μm column: 30 ℃, injection volume: 10 μ L, flow rate: 1.0mL/min, evaporation temperature: 40 ℃, carrier gas flow rate: 2.5L/min, mobile phase: 100% methanol.
The HPLC retention time of each component was: oleic acid-phytosphingosine ceramide 11.3min, linoleic acid-phytosphingosine ceramide 9.5min, palmitic acid-phytosphingosine ceramide 10.7min, stearic acid-phytosphingosine ceramide 13.9min, linolenic acid-phytosphingosine ceramide 8.2min.
Separating the obtained product by preparative high performance liquid chromatography to obtain oleic acid-phytosphingosine ceramide, palmitic acid-phytosphingosine ceramide, linoleic acid-phytosphingosine ceramide, stearic acid-phytosphingosine ceramide, and linolenic acid-phytosphingosine ceramide (nuclear magnetic hydrogen spectrum is consistent with standard spectrum), with mass ratio of 21.3%, 10.5%, 63.2%, 2.4%, 0.4%, and the balance of other components with less content. In this example, a domestic olive oil fatty acid was used, the main component of which was linoleic acid, and the resulting product was mainly linoleic acid ceramide.
Example 2
Synthesis of ceramide from olive oil fatty acid and sphingosine
The first step is as follows: 50g of olive oil grease is dissolved in 60mL of tetrahydrofuran, cooled in ice bath, 100mL of potassium hydroxide (25 wt%) solution is added dropwise, and the mixture is heated to room temperature after the dropwise addition is finished to react until the TLC detection reaction is finished.
And (3) post-treatment: adding dilute hydrochloric acid (3N) to adjust the pH value of the reaction system to 3, adding 150mL ethyl acetate to extract the aqueous phase, adding 100mL saturated saline water to wash once, and adding anhydrous Na into the organic phase 2 SO 4 Drying, filtering and vacuum concentrating to obtain 40g olive oil fatty acid.
The second step is that: mixing olive oil fatty acid (50 mmol, molecular weight is calculated as oleic acid), EDCI (75 mmol), et 3 Adding N (75 mmol) into 250mL of the mixture, adding 100mL of dichloromethane into the mixture, stirring the mixture at room temperature for 1 hour, adding sphingosine (50 mmol) into the reaction system, stirring the mixture at room temperature until TLC detectionAnd (4) finishing the reaction.
And (3) post-treatment: adding water to quench and react, separating an organic layer, drying, filtering, concentrating in vacuum, washing by a solvent to obtain the olive oil ceramide, analyzing a product by HPLC, and carrying out HPLC chromatographic conditions: using Shimadzu high performance liquid chromatograph (LC-2030C 3DPlus), the mixture was purified by Innoval ODS-2.6 × 250mm,5 μm column, column temperature: 30 ℃, injection volume: 10 μ L, flow rate: 1.0mL/min, evaporation temperature: 40 ℃, carrier gas flow rate: 2.5L/min, mobile phase: (2 wt% water +98wt% methanol) each contained 0.1wt% formic acid.
The HPLC retention time of each component was: oleic acid-sphingosine ceramide 20.7min, linoleic acid-sphingosine ceramide 16.6min.
Separating the obtained product by preparative high performance liquid chromatography to obtain oleic acid-sphingosine ceramide, palmitic acid-sphingosine ceramide, linoleic acid-sphingosine ceramide, stearic acid-sphingosine ceramide, and linolenic acid-sphingosine ceramide (nuclear magnetic hydrogen spectrum is consistent with standard spectrum), with mass ratio of 61.8%, 12.6%, 19.3%, 3.4%, and 0.6%, and other components with less content. This example uses imported olive oil fatty acid, the main component of which is oleic acid, the resulting product being predominantly oleic ceramide.
Oleic acid-sphingosine ceramide hydrogen profile: 1 h NMR (400mhz, methanol-d 4) δ 7.70 (d, J =8.9hz, 1h), 5.69 (dt, J =15.3,6.7hz, 1h), 5.45 (dd, J =15.4,7.5hz, 1h), 5.34 (t, J =4.9hz, 2h), 4.03 (t, J =7.5hz, 1h), 3.85 (ddd, J =9.5,4.6,2.4hz, 1h), 3.68 (d, J =5.0hz, 2h), 2.19 (t, J =7.6hz, 2h), 2.03 (q, J =6.9, 6.4hz, 6h), 1.64-1.51 (m, 2H), 1.30 (d, J =14.5hz, 41h), 0.90 (t, J = 6.0h, 6.7h). Linoleic acid-sphingosine ceramide hydrogen spectrum: 1 H NMR(400MHz,Methanol-d4)δ7.69(d,J=8.9Hz,1H),5.69(dt,J=15.3,6.7Hz,1H),5.46(dd,J=15.3,7.4Hz,1H),5.41–5.25(m,4H),4.03(t,J=7.5Hz,1H),3.85(tdd,J=7.5,4.7,2.2Hz,1H),3.68(d,J=5.0Hz,2H),2.77(t,J=6.4Hz,2H),2.20(q,J=7.6,6.9Hz,2H),2.13–1.94(m,6H),1.67–1.49(m,2H),1.31(d,J=19.6Hz,40H),0.90(td,J=6.8,3.8Hz,6H)。
example 3
Synthesis of ceramide from olive oil fatty acid and dihydrosphingosine
The first step is as follows: 50g of olive oil grease is dissolved in 60mL of tetrahydrofuran, cooled in ice bath, 100mL of potassium hydroxide (25 wt%) solution is added dropwise, and the mixture is heated to room temperature after the dropwise addition is finished to react until the TLC detection reaction is finished.
And (3) post-treatment: adding dilute hydrochloric acid (3N) to adjust pH to 3, adding 150mL ethyl acetate to extract water phase, adding 100mL saturated salt water to wash once, adding anhydrous Na to organic phase 2 SO 4 Drying, filtration and vacuum concentration gave 40g of olive oil fatty acid.
The second step is that: mixing olive oil fatty acid (50 mmol, molecular weight is calculated as oleic acid), EDCI (100 mmol), et 3 N (100 mmol) was added to 250mL in a round-bottom flask, followed by addition of 100mL of methylene chloride, followed by stirring at room temperature for 1 hour, followed by addition of sphinganine (75 mmol) to the reaction system, followed by stirring at room temperature until completion of the TLC detection reaction.
And (3) post-treatment: adding water to quench and react, separating an organic layer, drying, filtering, concentrating in vacuum, washing by a solvent to obtain the olive oil ceramide, analyzing a product by HPLC, and carrying out HPLC chromatographic conditions: using Shimadzu high performance liquid chromatograph (LC-2030C 3DPlus), the column temperature was adjusted by Innoval ODS-2.6 × 250mm,5 μm column: 30 ℃, injection volume: 10 μ L, flow rate: 1.0mL/min, evaporation temperature: 40 ℃, carrier gas flow rate: 2.5L/min, mobile phase: (2 wt% water +98wt% methanol) each contained 0.1wt% formic acid.
The HPLC retention time of each component was: oleic acid-sphinganine ceramide 23.6min, linoleic acid-sphinganine ceramide 19.1min.
Separating the obtained product by preparative high performance liquid chromatography to obtain oleic acid-sphinganine ceramide, palmitic acid-sphinganine ceramide, linoleic acid-sphinganine ceramide, stearic acid-sphinganine ceramide, and linolenic acid-sphinganine ceramide (nuclear magnetic hydrogen spectrum is consistent with standard spectrum), with mass ratio of 29.9%, 18.2%, 45.1%, 2.3%, and 0.9%. The balance of other components with less content.
Oleic acid-dihydrosphingosine ceramide hydrogen profile: 1 h NMR (400mhz, methanol-d 4) δ 5.34 (t, J =4.9hz, 2h), 3.81 (q, J =5.6hz, 1h), 3.75-3.65 (m, 2H), 3.65-3.51 (m, 1H), 2.22 (dd, J =9.2,5.4hz, 2h), 2.03 (q, J =6.3hz, 4h), 1.70-1.49 (m, 5H), 1.48-1.05 (m, 45H), 0.90 (t, J =6.6hz, 6h). Linoleic acid-sphinganine ceramide: 1 H NMR(400MHz,Methanol-d4)δ5.42–5.24(m,4H),3.89–3.75(m,1H),3.75–3.64(m,2H),3.64–3.53(m,1H),2.77(t,J=6.4Hz,2H),2.22(t,J=7.4Hz,2H),2.06(q,J=6.8Hz,4H),1.57(ddt,J=33.9,13.9,5.8Hz,4H),1.31(d,J=21.5Hz,40H),0.90(td,J=6.8,3.7Hz,6H)。
example 4
MTT method for detecting cell proliferation activity of compound
HaCaT cells were cultured at 1X 10 4 The density of cells/well was plated in 96-well plates overnight in an incubator. After 24h the supernatant was discarded, 100. Mu.L of medium containing different concentrations of the product of example 1 was added, incubation was continued for 24h and the medium was removed, 100. Mu.L of thiazole blue (MTT) was added to each well, absorbance at 450nm was measured and cell viability = A was calculated Medicine feeding hole /A Blank hole ×100%。
As shown in fig. 1, the results show that the olive oil ceramide has a promoting effect on cell viability, and the cell viability is 102.7%, 121.2%, 145.2% and 165.2% respectively at the concentrations of 70, 150, 250 and 300mg/L, showing a significant cell proliferation promoting effect and having good tissue repair ability.
The proliferation activity of ceramide 3B (i.e., oleic acid ceramide) on cells was tested in the same manner, and as a result, as shown in fig. 2, the cell viability was 101.7%, 111.2%, 126.8%, 141.9% at concentrations of 70, 150, 250, 300mg/L, respectively, which was less effective in promoting cell proliferation and tissue repair than olive oil ceramide.
Example 5
Evaluation of skin Barrier repair by cell migration
The principle is as follows: when the cells grow to be fused into a monolayer, a blank area is made on the fused monolayer by a scratching tool, the cells in the blank area are removed by mechanical force, the migration of the cells to a cell-free area is observed through a period of culture, and the migration capability of the cells is reflected by measuring the migration distance of the cells.
The method comprises the following operation steps:
1. the plates were streaked. Firstly, a Marker pen is used on the back of a 6-hole plate, a straight ruler is used for uniformly drawing transverse lines which are about every 0.5-1 cm and cross through holes, each hole at least penetrates through 5 lines, and the lines are not too thick when drawing lines.
2. And (5) laying cells. About 5X 10 additions to the wells 5 And (3) inoculating each cell (the number of different cells is different and is adjusted according to the growth speed of the cells), wherein the inoculation principle is that the fusion rate reaches 100 percent after the overnight inoculation.
3. And (4) cell lineation. The next day, the cell layer was scored with a tip perpendicular to the cell plane along the line drawn on the back of the plate on the first day (preferably the same tip is used between different wells).
4. The cells were washed. After the scoring was completed, cells were washed 3 times with sterile PBS, non-adherent cells were washed away, i.e., cells streaked during streaking, leaving a clear gap after streaking, and then fresh serum-free medium was replaced.
5. And (5) culturing and observing cells. Diluting the sample (example 1 product, ceramide 3B) with the culture medium (concentration of 0.08 mM), adding to a cell culture dish, placing the cells at 37 deg.C, 5wt% 2 The cells were incubated in an incubator and taken out at 24h, microscopically observed and the width of the scratch was measured and photographed, and the healing rate was calculated using Image J software.
The results are shown in fig. 3, and the scratch width of the experimental group is narrower than that of the solvent control group, indicating that the olive oil ceramide has better tissue healing ability. The healing rate of the solvent control group after 24h was 31.25%, the healing rate of olive oil ceramide after 24h was 74.48%, and the healing rate of ceramide 3B after 24h was 59.32%. The compound provided by the invention obviously improves the cell healing rate, has good skin tissue repair activity, and has a better effect than ceramide 3B.
Example 6
Elastase inhibition experiments to test anti-aging effect
Elastase inhibition method: 2mL of 2mg/mL elastase solution is taken, added with the products of the embodiment 1 with different concentrations, fully and uniformly mixed by vortex, shaken in a shaking table at 37 ℃ and 400r/min for 20min, immediately added with 5mL of 0.5mol/L phosphate buffer solution with pH6.0, uniformly mixed by vortex, taken a proper amount of the uniformly mixed solution to a 2mL centrifugal tube, centrifuged for 10min at 9 x 391 g, the supernatant liquid is precisely absorbed into a 96-well plate, the absorbance is measured by an enzyme-labeling instrument at the wavelength of 495nm, and simultaneously spectral scanning of 400-800 nm is carried out.
And taking a substrate and enzyme solution as a blank control group, taking a substrate and enzyme solution and a sample solution as an enzyme inhibition group, and taking the substrate and sample without the enzyme solution as background. Each group is provided with 3 holes. Inhibition (%) = [1- (An-An ')/(A0-A0') ]. Times.100%, wherein A0 is the absorbance of a sample without adding An enzyme, A0 'is the absorbance of a sample without adding only a substrate and An enzyme, an is the absorbance of a solution with only a sample, and An' is the absorbance of a sample without adding An enzyme. If An ' > An, a promoting effect is exhibited, and the promoting rate (%) = [1- (An ' -An)/(A0-A0 ') ] × 100%.
As shown in FIG. 4, the olive oil ceramide has a good inhibitory effect on elastase at different concentrations, specifically, the inhibitory rate on elastase is 11.13% at a concentration of 250mg/L, 21.67% at a concentration of 500mg/L, 30.26% at a concentration of 1000mg/L, and 19.81% at a concentration of 2000 mg/L.
The inhibitory activity of ceramide 3B against elastase was tested in the same manner, and the elastase inhibitory effect at a concentration of 582mg/L (i.e., 1 mmol/L) was 9.76%, which was not as good as that of olive oil ceramide at a similar concentration.
Example 7
LPS induced cell method for detecting anti-inflammatory repair effect
B16 mouse melanoma cells at a density of 1X 10 4 One/well is planted in a 96-well plate, the 96-well plate is placed in an incubator and is adhered to the wall overnight, supernatant is discarded after 24 hours, 100 mu L of the product of the example 1 with different concentrations diluted by DMEM medium is added, a negative control group is DMEM medium without samples, 3 wells are added in each group, and the weight of the negative control group is 5wt% of the DMEM medium without samples%CO 2 And incubating at 37 ℃. After 2h administration, the LPS model group and the experimental group were added with 10. Mu.g/mL LPS and incubated together for 24h. After the reaction, 50. Mu.L of cell supernatant was collected and the expression of IL-6 gene in the cells was detected by using IL-6ELISA kit.
The results are shown in FIG. 5, where IL-6 levels were 12.51-fold higher than basal levels when stimulated with LPS at a working concentration of 10. Mu.g/mL. Under the action of the olive oil ceramide with the concentrations of 50mg/L, 100mg/L, 200mg/L and 400mg/L respectively, the IL-6 factor level is obviously reduced and is 11.13 times and 10.26,8.31,6.10 times of the basic level respectively, and the dose dependence is formed, so that the olive oil ceramide has a good anti-inflammatory effect and can promote the repair of inflammatory damaged skin.
Example 8
MMP1 is also called interstitial collagenase and matrix metalloproteinase, belongs to the family of matrix metalloproteinase, and has the main function of a substrate, namely fibrous collagen, degrading collagen fibers and gelatin in extracellular matrix and changing microenvironment of cells. MMP1 plays an important role in elastin, inhibition of MMP1 can improve synthesis of collagen and elastin of fibroblasts, and reduction of MMP activity can increase collagen synthesis speed.
HaCaT cells were cultured at 1X 10 5 The density of cells/well was plated in 96-well plates overnight in an incubator. After 24h, the supernatant was discarded, 100. Mu.L of the medium containing the product of example 1 at various concentrations (no drug was added to the model group), and the negative control group was DMEM medium containing no drug, 3 multiple wells each, and the CO was reduced at a mass fraction of 5% 2 After incubation at 37 ℃ for 2h, UVA ultraviolet radiation was applied. The distance between the ultraviolet radiation source and the cell was 15cm, and the UVA intensity was 200mJ/cm 2 The radiation time is 1.5h, and after the radiation is finished, the incubation is continued in the incubator for 12h. MMP-1 gene expression in cells was detected using an MMP-1ELISA kit.
As shown in FIG. 6, the MMP1 expression level of the negative control group was 1, the MMP1 expression level of the model group was 1.67, the concentration of olive oil ceramide was 50mg/L, the MMP1 expression level was 1.50, the MMP1 expression level was 1.39 at a concentration of 100mg/L, the MMP1 expression level was 1.32 at a concentration of 150mg/L, and the MMP1 expression level was 1.34 at a concentration of 200mg/L, and the inhibitory effect on MMP1 was more significant at higher concentrations.
After UVA ultraviolet radiation, keratinocytes promote increased fibroblast MMP1 expression, thereby causing degradation of skin extracellular matrix and skin collagen, resulting in skin photoaging. The results show that the olive oil ceramide can inhibit fibroblast cells caused by ultraviolet radiation from generating MMP1, and has certain effect on preventing skin photoaging.
Example 9
DPPH free radical scavenging and detecting antioxidant performance
DPPH is 1,1-diphenyl-2-trinitrophenylhydrazine, and can be used for antioxidant experiments.
Samples of corresponding concentrations (50, 100, 200, 400, 800 mg/L) were mixed with 0.1mol/L DPPH, absolute ethanol solution at a ratio of 1:1, and mixing DPPH and absolute ethyl alcohol in a volume ratio of 1:1, mixing the mixture in equal volume, reacting the mixture for 30min in a dark place at room temperature, and measuring the light absorption value at 517 nm. The absorbance of the sample and the DPPH reaction solution was denoted as A1, the absorbance of the sample and the absolute ethanol reaction solution was denoted as A2, the absorbance of the DPPH and the absolute ethanol reaction solution was denoted as A3, and the DPPH clearance of the sample = [1- (A1-A2)/A3 ] × 100%.
As shown in FIG. 7, the DPPH radical scavenging rates at concentrations of 50, 100, 200, 400, and 800mg/L were 29.42%, 39.49%, 46.77%, 55.26%, and 67.01, respectively, and excellent antioxidant effect was exhibited. Ceramide 3B (i.e., oleic ceramide) was tested for antioxidant effect in the same manner, and as shown in FIG. 8, DPPH radical scavenging rates at concentrations of 50, 100, 200, 400, 800mg/L were 7.76%, 12.82%, 24.10%, 29.60%, 33.16%. The clearance rate of olive oil ceramide on DPPH is higher than that of ceramide 3B (oleic acid ceramide), and the olive oil ceramide has better antioxidant effect.
Example 10
Whitening Activity test
Taking B16 cells in exponential growth phase, digesting with trypsin-EDTA with the mass fraction of 0.25%, blowing uniformly, and mixing the cells according to the proportion of 3 multiplied by 10 5 The density of each well was seeded in 12-well plates. At 37 ℃ and 5% by mass of CO 2 Culturing in the environmentOvernight. Discarding supernatant, adding culture solution containing samples with different mass concentrations, incubating with RPMI-1640 medium without drug as blank group, incubating with DMEM medium as molding group, each group having 3 multiple wells, and making CO content of 5% by mass 2 And incubating for 24 hours at 37 ℃. After the medium in the well plate was discarded and washed once to twice with Phosphate Buffered Saline (PBS), 1mL of a NaOH solution (1 mol/L) containing 10% by mass of DMSO was added and the mixture was incubated at 80 ℃ or 100 ℃ for 2 hours until the cells were completely lysed. The sample was placed in a microplate reader and absorbance was measured at 405 nm. Melanin production inhibition rate = (each well OD value/blank group OD value) × 100% was calculated.
As a result, as shown in fig. 9, the melanin of the model group was 157.36%, and the melanin inhibition ratios of olive oil ceramide were 147.77%, 131.84%, 120.56%, 108.82%, and 96.28% at concentrations of 10, 20, 40, 80, and 100mg/L, respectively, and olive oil ceramide showed excellent whitening effects.
The above description is only an embodiment of the present invention, but the scope of the present invention is not limited thereto, and any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope of the present invention are included in the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
Claims (10)
1. An olive oil ceramide, which is obtained by reacting an olive oil fatty acid with a sphingoid compound selected from sphingosine, phytosphingosine, dihydrosphingosine.
2. The olive oil ceramide according to claim 1, wherein the olive oil fatty acid is obtained from hydrolysis of olive oil.
3. The olive oil ceramide according to claim 1 or 2, wherein the olive oil fatty acid contains 20 to 83wt% oleic acid and 3.5 to 70wt% linoleic acid.
4. Olive oil ceramide, the composition of which comprises: oleic acid ceramide, linoleic acid ceramide, palmitic acid ceramide, stearic acid ceramide, linolenic acid ceramide.
5. The olive oil ceramide according to claim 4, whose composition comprises: 20 to 83 weight percent of oleic acid ceramide, 7.5 to 20 weight percent of palmitic acid ceramide, 3.5 to 70 weight percent of linoleic acid ceramide, 0.5 to 5 weight percent of stearic acid ceramide and 0.1 to 1.0 weight percent of linolenic acid ceramide.
6. The olive oil ceramide according to claim 4 or 5, the composition of which further comprises: 0 to 3.5 weight percent of palmitoleic acid ceramide, 0 to 0.6 weight percent of arachidic acid ceramide, 0 to 0.4 weight percent of eicosenoic acid ceramide, 0 to 0.3 weight percent of heptadecanoic acid ceramide, 0 to 0.3 weight percent of heptadecenoic acid ceramide, 0 to 0.2 weight percent of behenic acid ceramide, 0 to 0.2 weight percent of tetracosanoic acid ceramide, and 0 to 0.05 weight percent of myristic acid ceramide.
7. The method for synthesizing olive oil ceramide according to any one of claims 1 to 6, comprising the steps of:
reacting olive oil fatty acid with sphingoid compound under the condition of condensing agent, wherein the condensing agent is EDCI and Et 3 N;
The olive oil fatty acid, sphingoid compound, EDCI, et 3 The molar ratio of N is 1: (1-1.5): (1-2): (1-2), wherein the solvent for reaction is at least one of dichloromethane, tetrahydrofuran, ethyl acetate and acetonitrile.
8. Use of the olive oil ceramide as claimed in any one of claims 1 to 6 in cosmetics, pharmaceuticals, dietary foods or health products.
9. The use according to claim 8, wherein said olive oil ceramide has at least one of skin barrier repair, tissue healing, anti-aging, anti-inflammatory, anti-photoaging, anti-oxidant, collagen synthesis promotion, elastin enhancement, and whitening efficacy.
10. A composition comprising the olive oil ceramide of any one of claims 1 to 6, having at least one of skin barrier repair, tissue healing, anti-aging, anti-inflammatory, anti-photoaging, anti-oxidant, collagen synthesis promoting, elastin enhancement, and whitening effects.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211493023.1A CN115894279A (en) | 2022-11-25 | 2022-11-25 | Olive oil ceramide and synthesis method and application thereof |
PCT/CN2023/133524 WO2024109867A1 (en) | 2022-11-25 | 2023-11-23 | Vegetable oil ceramides, synthesis method therefor, and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211493023.1A CN115894279A (en) | 2022-11-25 | 2022-11-25 | Olive oil ceramide and synthesis method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115894279A true CN115894279A (en) | 2023-04-04 |
Family
ID=85731743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211493023.1A Pending CN115894279A (en) | 2022-11-25 | 2022-11-25 | Olive oil ceramide and synthesis method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115894279A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115947666A (en) * | 2023-02-02 | 2023-04-11 | 深圳市迪克曼生物科技有限公司 | Rice bran oil ceramide and synthesis method and application thereof |
WO2024109867A1 (en) * | 2022-11-25 | 2024-05-30 | 深圳市迪克曼生物科技有限公司 | Vegetable oil ceramides, synthesis method therefor, and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170084950A (en) * | 2016-01-13 | 2017-07-21 | 주식회사 엘씨에스바이오텍 | Green-ceramides, compositions comprising the green-ceramides and method for preparing the green-ceramides |
US20190300917A1 (en) * | 2018-03-29 | 2019-10-03 | Evonik Degussa Gmbh | Process for preparing sphingolipids |
-
2022
- 2022-11-25 CN CN202211493023.1A patent/CN115894279A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170084950A (en) * | 2016-01-13 | 2017-07-21 | 주식회사 엘씨에스바이오텍 | Green-ceramides, compositions comprising the green-ceramides and method for preparing the green-ceramides |
US20190300917A1 (en) * | 2018-03-29 | 2019-10-03 | Evonik Degussa Gmbh | Process for preparing sphingolipids |
Non-Patent Citations (1)
Title |
---|
HYUN KYUNG CHOI 等: "Ceramide NPs derived from natural oils of Korean traditional plants enhance skin barrier functions and stimulate expressions of genes for epidermal homeostasis", 《J COSMET DERMATOL.》, vol. 21, 31 October 2022 (2022-10-31), pages 4931 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024109867A1 (en) * | 2022-11-25 | 2024-05-30 | 深圳市迪克曼生物科技有限公司 | Vegetable oil ceramides, synthesis method therefor, and use thereof |
CN115947666A (en) * | 2023-02-02 | 2023-04-11 | 深圳市迪克曼生物科技有限公司 | Rice bran oil ceramide and synthesis method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115894279A (en) | Olive oil ceramide and synthesis method and application thereof | |
US20090170787A1 (en) | Cosmetic composition containing hydrolysates of icariin | |
JP2009501160A (en) | Yaenari lactic acid bacteria culture, production method thereof, and cosmetic composition containing the culture | |
US7981460B2 (en) | Substituted benzyl ester derivative and use thereof | |
CN115974714A (en) | Shea butter ceramide, and its synthesis method and use | |
CN115947666A (en) | Rice bran oil ceramide and synthesis method and application thereof | |
CN115304509A (en) | Ceramide compound containing chain carboxylic acid and preparation method and application thereof | |
CN115974715A (en) | Peony seed oil ceramide, and synthesis method and application thereof | |
CN115974716A (en) | Cottonseed oil ceramide and synthesis method and application thereof | |
CN115947667A (en) | Coconut oil ceramide and synthesis method and application thereof | |
CN116023289A (en) | Avocado oil ceramide and synthesis method and application thereof | |
CN116003289A (en) | Watermelon seed oil ceramide and synthesis method and application thereof | |
CN116041205A (en) | Borage oil ceramide and synthetic method and application thereof | |
CN116041206A (en) | Safflower seed oil ceramide and its synthesis method and use | |
CN116003287A (en) | Sunflower seed oil ceramide and synthesis method and application thereof | |
CN116003286A (en) | Prinsepia utilis royle oil ceramide and synthesis method and application thereof | |
CN116023288A (en) | Grape seed oil ceramide and synthesis method and application thereof | |
CN116003288A (en) | Nanmei oleo ceramide and its synthesis method and use | |
JP2003073225A (en) | Cosmetic | |
CN115894278A (en) | Linolenic acid-derived ceramide, and preparation method and application thereof | |
EP2440551B1 (en) | Unsaturated fatty acid monoesters and diesters on ascorbic acid and cosmetic uses thereof | |
KR101418979B1 (en) | Compositions for promotion of collagen synthesis and cosmetics using the same | |
CN117304055A (en) | Perilla seed oil ceramide and synthesis method and application thereof | |
CN117326968A (en) | Tea oil ceramide and synthesis method and application thereof | |
CN117326965A (en) | Oenothera biennis oil ceramide and its synthesis method and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |